Indaptus Therapeutics, Inc. (INDP)
| Market Cap | 8.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.02M |
| Shares Out | 14.43M |
| EPS (ttm) | -1.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 178,669 |
| Open | 0.6300 |
| Previous Close | 0.6500 |
| Day's Range | 0.5801 - 0.6200 |
| 52-Week Range | 0.5800 - 3.1000 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+1,340.68%) |
| Earnings Date | Mar 13, 2025 |
About INDP
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for INDP stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 1,340.68% from the latest price.
News
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announc...
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections...
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections...
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announces financial results for the fourth quarter and fiscal year ended Dec...
Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler, will present at Tribe Public's Webinar Presentation and Q&A Event...
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections...
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections,...
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infe...
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025 Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Mome...
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infectio...
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or tar...
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferenc...
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present post...
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Di...
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended Dec...
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments,...
European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology
Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza Patent will provide additional protection covering a compositi...
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 an...
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4 , 2023
Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler will present at Tribe Public's Webinar Presentation and Q&A Event ...
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. ...
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and pr...